CAR T Bridging for MM: Module

CME

The Role of Bridging Therapeutic Strategies for Patients With Multiple Myeloma Receiving CAR T-Cell Therapy

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: July 17, 2023

Expiration: July 16, 2024

Thomas G. Martin
Thomas G. Martin, MD

Activity

Progress
1
Course Completed

References

  1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: multiple myeloma. V.3.2023. nccn.org. Accessed July 3, 2023.
  2. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086-1107. 
  3. Bruno B, Wäsch R, Engelhardt M, et al. European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma. Haematologica. 2021;106:2054-2065.
  4. Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168:724-740.
  5. Beaupierre A, Kahle N, Lundberg R, et al. Educating multidisciplinary care teams, patients, and caregivers on CAR T-cell therapy. J Adv Pract Oncol. 2019;10(suppl 3):29-40.
  6. Idecabtagene vicleucel [prescribing information]. Summit, NJ: Celgene; 2021.
  7. Ciltacabtagene autoleucel [prescribing information]. Horsham, PA: Janssen Biotech, Inc; 2023.
  8. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705-716.
  9. Anderson LD, Munshi NC, Shah N, et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results. Presented at: 2021 American Society of Clinical Oncology Annual Meeting I; June 4-8, 2021. Abstract 8016.
  10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314-324.
  11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265-1274.
  12. Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 8009.
  13. June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361-1365.
  14. MD Anderson. IEC therapy toxicity assessment and management. www.mdanderson.org/documents/for-physicians/algorithms/clinical-management/clin-management-cytokine-release-web-algorithm.pdf. Accessed July 3, 2023.
  15. Wong SW, Richard S, Lin, et al. Anakinra targeting cytokine release syndrome associated with chimeric antigen receptor T-cell therapies. Presented at: 2021 American Society of Hematology Annual Meeting; December 11-14, 2022. Abstract 2812.
  16. Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47-62.
  17. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625-638.
  18. Hansen DK, Sidana S, Peres LC, et al. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol. 2023;41:2087-2097.
  19. Kauer J, Sester LS, Kriegsmann K, et al. Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma. Hematol Oncol. 2023;Epub ahead of print.
  20. Zafar AA, Huang CY, Lo M, et al. Intensity of cyclophosphamide-based bridging regimens before CAR-T therapy in myeloma. Transplant Cell Ther. 2023;S2666-6367(23)01299-X. 
  21. Alsina M, Dhodapkar M, Berdeja J, et al. Idecabtagene vicleucel (ide-cel) in patients with an inadequate response to frontline autologous stem cell transplantation (ASCT): results from KarMMa-2 cohort 2c. Presented at: 2023 European Hematology Association Annual Meeting; June 8-11, 2023. Abstract P871.
  22. Usmani S, Patel K, Hari P, et al. KarMMa-2 Cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 704.
  23. Cohen AD, Mateos MV, Cohen YC, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141:219-230.
  24. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002-1014.
  25. San Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;Epub ahead of print.
  26. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207-221.
  27. Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495-505.
  28. Teclistamab-cqyv [prescribing information]. Horsham, PA: Janssen Biotech, Inc; 2022.
  29. Raje N, Bahlis NJ, Costello C, et al. Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 158.
  30. Bahlis NJ, Tomasson MH, Mohty M, et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma naive to B-cell maturation antigen (BCMA)-directed therapies. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 159. 
  31. D'Souza A, Shah N, Rodriguez C, et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2022;40:3576-3586.
  32. Lee HC, Bumma N, Richter JR, et al. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 8006.
  33. Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232-2244.
  34. Chari A, Touzeau C, Schinke C, et al. Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): phase 1/2 results from MonumenTAL-1. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 157.
  35. Trudel S, Cohen AD, Krishnan AY, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Presented at: 2021 American Society of Hematology Annual Meeting; December 10-13, 2021. Abstract 653.
  36. Depil S, Duchateau P, Grupp SA, et al. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185-199.
  37. Mailankody S, Matous JV, Chhabra S, et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023;29:422-429.
  38. Charlinski G, Vesole DH, Jurczyszyn A. Rapid progress in the use of immunomodulatory drugs and cereblon E3 ligase modulators in the treatment of multiple myeloma. Cancers. 2021;13:4666.
  39. Lonial S, Popat R, Hulin C, et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol. 2022;9:e822-e832.
  40. Lonial S, Abdallah AO, Answer F, et al. Iberdomide (IBER) in combination with dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM): results from the anti-B-cell maturation antigen (BCMA)-exposed cohort of the CC-220-MM-001 trial. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 653.
  41. Van de Donk N, Popat R, Larsen J, et al. First results of iberdomide (IBER; CC-220) in combination with dexamethasone (DEX) and daratumumab (DARA) or bortezomib (BORT) in patients with relapsed/refractory multiple myeloma (RRMM). Presented at: 2020 American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 724.
  42. Richardson PJ, Trudel S, Quach H, et al. Mezigdomide (CC-92480), a potent, novel cereblon E3 ligase modulator (CELMoD), combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): preliminary results from the dose-expansion phase of the CC-92480-MM-001 trial. Presented at: 2022 American Society of Hematology Annual Meeting; December 10-13, 2022. Abstract 568.